Research Summary
John Kurhanewicz, PhD is a Professor in Residence in the Departments of Radiology and Biomedical Imaging, Urology and Pharmaceutical Chemistry at University of California, San Francisco, and a member of the California Institute for Quantitative Biology and UCSF Cancer Center, and faculty in the UCSF-UCB Bioengineering Graduate Group. He is the Director of the UCSF Body Research Interest Group, the Biomedical NMR lab, and the Kurhanewicz Laboratory at UCSF. Dr. Kurhanewicz received his BS in Chemistry from the University of South Florida/New College in 1982, and obtained his PhD in Physical Organic Chemistry from the University of South Florida, Tampa in 1987, followed by a postdoctoral fellowship in MRI/MRS from the University of California, San Francisco in 1990.
Dr. Kurhanewicz and his colleagues have developed a large prostate cancer imaging program at UCSF, involving the application of advanced magnetic resonance imaging techniques (metabolic, diffusion and perfusion weighted MRI) to provide a more accurate assessment of the extent and aggressiveness of prostate cancer in individual patients. This multiparametric 1H MRI prostate cancer staging exam is currently being used to help over a 1,000 men diagnosed with prostate cancer a year at UCSF to decide on their best therapeutic course. He is also currently involved in the development and clinical translation of an extraordinary new molecular imaging technique utilizing hyperpolarized 13C labeled metabolic substrates that has the potential to revolutionize the way MR imaging is used in the risk assessment of prostate cancer patients. He led the first clinical trial of this technology at UCSF and is involved in three ongoing clinical trials investigating its clinical utility.
Dr. Kurhanewicz has published over 230 peer-reviewed manuscripts and19 book chapters, and has been cited 16,089 times (citation indices: h-index of 69, i10-index - 180). He is a member of 7 scientific societies, serves on numerous scientific review panels for the National Institute of Health, Department of Defense and American Cancer Society and reviews for over 20 different journals. He has 25 years of mentoring in the areas of advanced MR cancer imaging and molecular imaging, and has mentored over 120 graduate and under-graduate students, medical fellows and junior faculty.
Research Funding
September 7, 2020 - August 31, 2025 - Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U24CA253377
September 1, 2017 - July 31, 2022 - Metabolic imaging comparisons of patient-derived models of renal cell carcinoma , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U01CA217456
June 1, 2017 - May 31, 2022 - Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA215694
April 15, 2021 - April 14, 2022 - High Field MRI For Optimized Translational 1H Multiparametric and Multinuclear Imaging Research , Principal Investigator . Sponsor: NIH, Sponsor Award ID: S10OD030256
Education
New College, Sarasota, FL, B.S., 1976-1982, Chemistry
University of South Florida, Tampa, FL, Ph.D., 1982-1987, Chemistry
University of California San Francisco, CA, Post-Doc., 1987-1990, In vivo Spectroscopy